WO2011030351A3 - Compositions pharmaceutiques au goût masqué - Google Patents

Compositions pharmaceutiques au goût masqué Download PDF

Info

Publication number
WO2011030351A3
WO2011030351A3 PCT/IN2010/000589 IN2010000589W WO2011030351A3 WO 2011030351 A3 WO2011030351 A3 WO 2011030351A3 IN 2010000589 W IN2010000589 W IN 2010000589W WO 2011030351 A3 WO2011030351 A3 WO 2011030351A3
Authority
WO
WIPO (PCT)
Prior art keywords
taste
tablets
pde
pharmaceutical compositions
inhibitor
Prior art date
Application number
PCT/IN2010/000589
Other languages
English (en)
Other versions
WO2011030351A2 (fr
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Original Assignee
Rubicon Research Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Private Limited filed Critical Rubicon Research Private Limited
Publication of WO2011030351A2 publication Critical patent/WO2011030351A2/fr
Publication of WO2011030351A3 publication Critical patent/WO2011030351A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

La présente invention concerne des compositions pharmaceutiques au goût masqué comprenant des inhibiteurs de phosphodiestérase-5 (PDE-5). Lesdites compositions pharmaceutiques au goût masqué pour administration orale comprennent au moins un inhibiteur de PDE-5, au moins un agent masqueur de goût, et au moins un excipient pharmaceutiquement acceptable. En outre, les compositions d'inhibiteur de PDE-5 au goût masqué sont fournies sous la forme de formulations au goût agréable adaptées à une administration orale, telle que des comprimés à désintégration orale, des comprimés à dispersion rapide, des comprimés croquables, des comprimés dispersibles, et des comprimés effervescents ou analogues. L'invention porte en outre sur un procédé de masquage du goût désagréable de l'inhibiteur de PDE-5.
PCT/IN2010/000589 2009-09-03 2010-09-03 Compositions pharmaceutiques au goût masqué WO2011030351A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2021MU2009 2009-09-03
IN2021/MUM/2009 2009-09-03

Publications (2)

Publication Number Publication Date
WO2011030351A2 WO2011030351A2 (fr) 2011-03-17
WO2011030351A3 true WO2011030351A3 (fr) 2011-06-30

Family

ID=43567799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000589 WO2011030351A2 (fr) 2009-09-03 2010-09-03 Compositions pharmaceutiques au goût masqué

Country Status (1)

Country Link
WO (1) WO2011030351A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130058160A (ko) * 2011-11-25 2013-06-04 한국유나이티드제약 주식회사 쓴맛이 차폐된 실데나필 시트레이트의 저작정 및 이의 제조방법
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
WO2013085276A1 (fr) * 2011-12-08 2013-06-13 에스케이케미칼 주식회사 Film pour administration orale contenant du mirodénafil ou l'un de ses sels pharmaceutiquement acceptables
WO2014092661A1 (fr) * 2012-01-18 2014-06-19 Mahmut Bilgic Formulations particulaires de tadalafil sous forme effervescente
WO2013109221A1 (fr) * 2012-01-18 2013-07-25 Mahmut Bilgic Nouvelles formulations effervescentes comprenant une composition édulcorante
EP2641477B2 (fr) 2012-03-19 2022-06-08 Symrise AG Compositions de matière
EP2867199B1 (fr) * 2012-07-02 2018-04-18 Hetero Research Foundation Compositions stables de fésotérodine
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
CN102727455B (zh) * 2012-07-03 2016-06-29 北京科信必成医药科技发展有限公司 一种他达那非口腔崩解片及其制备方法
KR101953735B1 (ko) * 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
WO2014148883A1 (fr) * 2013-03-20 2014-09-25 Natureceuticals Sdn Bhd Formulations d'herbes médicinales
CN104352461B (zh) * 2013-04-28 2017-07-14 南京海融医药科技股份有限公司 他达拉非的口服药物制剂
CN103271885A (zh) * 2013-05-23 2013-09-04 浙江华海药业股份有限公司 他达拉非口腔崩解片及其制备方法
EP3003285B1 (fr) * 2013-06-03 2022-02-16 McNeil AB Forme dosifiée pharmaceutique solide de libération d'au moins deux principes pharmaceutiques actifs dans la cavité buccale
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN104644574B (zh) * 2013-11-18 2017-08-01 深圳海王医药科技研究院有限公司 一种枸橼酸西地那非掩味制剂
EP3082428A4 (fr) * 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
KR101485177B1 (ko) * 2014-02-10 2015-01-23 한국유나이티드제약 주식회사 쓴맛이 차폐된 실데나필 시트레이트의 저작정 및 그 제조방법
CN105213333A (zh) * 2014-06-30 2016-01-06 深圳海王药业有限公司 一种他达拉非药物组合物及其制备方法
KR101561406B1 (ko) * 2015-02-02 2015-10-16 환인제약 주식회사 두타스테라이드 함유 고체 분산체 및 이를 포함하는 조성물
TN2017000507A1 (en) 2015-07-07 2019-04-12 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US10342886B2 (en) 2016-01-26 2019-07-09 S.C. Johnson & Son, Inc. Extruded wax melt and method of producing same
US10010638B2 (en) 2016-06-14 2018-07-03 S. C. Johnson & Son, Inc. Wax melt with filler
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
CN107694476B (zh) * 2017-07-25 2020-07-10 江苏远鸿新材料科技有限公司 一种高强度球型干燥剂的成型制造方法
WO2019081451A1 (fr) * 2017-10-26 2019-05-02 Mw Encap Limited Formulations remplies liquides d'inhibiteurs de pde5
IT201800003507A1 (it) * 2018-03-13 2019-09-13 Fulton Medicinali S P A Compressa sublinguale comprendente sildenafil citrato
JP2021535908A (ja) * 2018-08-31 2021-12-23 イマラ インク． 鎌状赤血球症を処置するためのｐｄｅ９阻害剤
CN111110683B (zh) * 2018-10-31 2023-08-15 广东东阳光药业股份有限公司 一种索利那新掩味组合物及其制备方法
CA3137260A1 (fr) * 2019-04-18 2020-10-22 Ellamed Ip & Services Pte. Ltd. Compositions liquides de citrate de sildenafil
KR102249155B1 (ko) * 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
WO2022216294A1 (fr) 2021-04-09 2022-10-13 Auson Pharmaceuticals Inc. Poudre pour suspension orale contenant du tadalafil
CN114957332A (zh) * 2022-05-30 2022-08-30 苏州正永生物医药有限公司 一种阿伐那非磷酸酯类化合物及其制备方法和应用
EP4316468A1 (fr) * 2022-08-03 2024-02-07 Recordati Industria Chimica E Farmaceutica SPA Complexation innovante d'extrait de serenoa lipido-stérol avec du tadalafil
CN115990140A (zh) * 2023-02-15 2023-04-21 北京悦康科创医药科技股份有限公司 一种那非类化合物冻干片及其制备方法
CN117243927A (zh) * 2023-10-17 2023-12-19 深圳市泰力生物医药有限公司 含安全有效掩味剂的盐酸卡利拉嗪口溶膜制剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017976A1 (fr) * 2002-08-21 2004-03-04 Phoqus Pharmaceuticals Limited, Forme psologique orale a gout masque, a dissolution rapide et comprenant du sildenafil
WO2004087111A1 (fr) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales a gout masque
WO2006047493A2 (fr) * 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2009074995A1 (fr) * 2007-12-10 2009-06-18 Ajanta Pharma Limited Compositions à croquer de citrate de sildénafil au goût masqué

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
KR20060093355A (ko) 1999-08-03 2006-08-24 릴리 아이코스 엘엘씨 베타-카르볼린 약학 조성물
CA2599378A1 (fr) 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Tadalafil possedant des dimensions importantes des particules et procede de fabrication correspondant
CA2612917A1 (fr) 2005-06-23 2007-01-04 Schering Corporation Formulations orales a absorption rapide d'inhibiteurs de la pde5
ES2308750T3 (es) 2005-08-29 2008-12-01 Teva Pharmaceutical Industries Ltd Tadalafil en particulas solidas que presenta una distribucion de particulas bimodal.
CA2622200A1 (fr) 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
AU2007232098A1 (en) 2006-03-31 2007-10-11 Rubicon Research Private Limited Directly compressible composite for orally disintegrating tablets
WO2008005039A1 (fr) 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions solides comprenant du tadalafil et au moins un véhicule

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017976A1 (fr) * 2002-08-21 2004-03-04 Phoqus Pharmaceuticals Limited, Forme psologique orale a gout masque, a dissolution rapide et comprenant du sildenafil
WO2004087111A1 (fr) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales a gout masque
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2006047493A2 (fr) * 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
US20060105039A1 (en) * 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2009074995A1 (fr) * 2007-12-10 2009-06-18 Ajanta Pharma Limited Compositions à croquer de citrate de sildénafil au goût masqué

Also Published As

Publication number Publication date
WO2011030351A2 (fr) 2011-03-17

Similar Documents

Publication Publication Date Title
WO2011030351A3 (fr) Compositions pharmaceutiques au goût masqué
WO2011110939A3 (fr) Compositions pharmaceutiques de benzhydrylpipérazines substituées
WO2010046933A3 (fr) Compositions pharmaceutiques de linézolid à goût masqué
MX2008000087A (es) Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
WO2008040534A3 (fr) Formes pharmaceutiques à base de film non muco-adhésif
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
WO2010116385A3 (fr) Compositions pharmaceutiques pour atténuer un goût désagréable
WO2005069933A3 (fr) Procedes permettant de traiter une maladie de type inflammatoire
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
WO2008085765A3 (fr) Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur
SG166115A1 (en) Pharmaceutical preparation containing meloxicam
WO2009084017A3 (fr) Comprimés de chlorhydrate de mémantine à dissolution orale et au goût masqué
WO2008038003A3 (fr) Compositions pharmaceutiques
WO2007100614A3 (fr) FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE
EP2142549A4 (fr) Dérivés d'adénosine, procédé pour la synthèse de ces derniers, et compositions pharmaceutiques pour la prévention et le traitement de maladies inflammatoires contenant lesdits dérivés en tant qu'ingrédients actifs
WO2010028173A3 (fr) Procédé de traitement de fibrillation auriculaire
TW200600098A (en) Solid orally ingestible formulations of tetrodotoxin
WO2006094799A3 (fr) Nouveaux composes heterocycliques
WO2008001201A3 (fr) Compositions pharmaceutiques de clopidogrel
WO2009045795A3 (fr) Formulations galéniques de composés organiques
WO2007131070A3 (fr) Compositions, formes pharmaceutiques et méthodes de traitement des vomissements
WO2006115770A3 (fr) Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale
WO2008035380A3 (fr) Procédé amélioré de préparation de formotérol de grande pureté et de ses sels pharmaceutiquement acceptables
WO2008081268A3 (fr) Compositions pharmaceutiques d'entacapone
PL1806130T3 (pl) Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10803268

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10803268

Country of ref document: EP

Kind code of ref document: A2